See more : Handelsinvest Virksomhedsobligationer (HAIVOB.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Celldex Therapeutics, Inc. (CLDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celldex Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vine Hill Capital Investment Corp. (VCIC) Income Statement Analysis – Financial Results
- Azplanning Co.,Ltd. (3490.T) Income Statement Analysis – Financial Results
- Delphax Technologies Inc. (DLPX) Income Statement Analysis – Financial Results
- Danske Invest Fonde (DKIFO.CO) Income Statement Analysis – Financial Results
- Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) Income Statement Analysis – Financial Results
Celldex Therapeutics, Inc. (CLDX)
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M | 11.20M | 9.27M | 46.79M | 15.18M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.70M | 3.35M | 763.20K | 1.48M | 2.20M | 1.20M | 1.10M | 4.00M | 7.00M | 9.00M | 6.60M | 10.20M | 10.90M | 7.80M | 4.60M | 2.20M | 100.00K |
| Cost of Revenue | 3.01M | 1.40M | 3.07M | 42.53M | 42.67M | 66.45M | 96.17M | 102.03M | 4.01M | 101.88M | 2.33M | 10.78M | 9.12M | 12.08M | 8.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 36.80K | -689.30K | -712.80K | -400.00K | -300.00K | -100.00K | 1.20M | 1.20M | 1.50M | 600.00K | 1.10M | 800.00K | 800.00K | 300.00K | -100.00K | 0.00 |
| Gross Profit | 3.88M | 957.00K | 1.58M | -35.12M | -39.10M | -56.91M | -83.43M | -95.24M | 1.47M | -98.30M | 1.78M | 427.00K | 146.00K | 34.72M | 6.78M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.66M | 3.31M | 1.45M | 2.20M | 2.60M | 1.50M | 1.20M | 2.80M | 5.80M | 7.50M | 6.00M | 9.10M | 10.10M | 7.00M | 4.30M | 2.30M | 100.00K |
| Gross Profit Ratio | 56.30% | 40.60% | 34.04% | -473.39% | -1,094.29% | -596.68% | -654.70% | -1,403.48% | 26.81% | -2,741.08% | 43.23% | 3.81% | 1.58% | 74.19% | 44.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.39% | 98.90% | 190.32% | 148.05% | 118.18% | 125.00% | 109.09% | 70.00% | 82.86% | 83.33% | 90.91% | 89.22% | 92.66% | 89.74% | 93.48% | 104.55% | 100.00% |
| Research & Development | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M | 100.17M | 104.38M | 67.40M | 47.40M | 32.44M | 27.65M | 26.17M | 26.35M | 18.50M | 18.07M | 14.06M | 13.87M | 10.02M | 14.71M | 21.58M | 10.77M | 7.87M | 5.70M | 5.30M | 6.00M | 8.00M | 8.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75B | 8.50B | 0.00 | 6.89B | 0.00 | 0.00 | 0.00 | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 0.00 | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.73B | -8.49B | 0.00 | -6.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75M | 8.50M | 8.24M | 6.89M | 5.57M | 5.35M | 5.59M | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 10.10M | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Other Expenses | 12.50M | 90.34M | 55.38M | 54.02M | 42.71M | 224.00K | 896.00K | 997.00K | 1.01M | 1.01M | 1.01M | 1.09M | 1.91M | 3.14M | 345.00K | 361.01K | 960.21K | 995.11K | 995.11K | 995.10K | 995.10K | 795.10K | 1.38M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 83.22M | 58.50M | 43.60M | 41.17M | 43.63M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.10M | 27.87M | 16.89M | 14.14M | 10.50M | 9.20M | 13.00M | 14.60M | 15.30M | 16.90M | 10.70M | 13.50M | 12.00M | 8.60M | 6.30M | 3.90M | 2.00M |
| Cost & Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 85.55M | 69.28M | 52.71M | 53.25M | 52.03M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.14M | 27.91M | 16.20M | 13.43M | 10.10M | 8.90M | 12.90M | 15.80M | 16.50M | 18.40M | 11.30M | 14.60M | 12.80M | 9.40M | 6.60M | 3.80M | 2.00M |
| Interest Income | 13.11M | 0.00 | 505.00K | 2.41M | 4.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 530.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.09M | 15.97M | 0.00 | 0.00 | 0.00 | 927.00K | 1.58M | 1.80M | 1.34M | 452.00K | 156.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.01M | 1.40M | 3.07M | 2.00M | 4.86M | 3.80M | 5.31M | 4.09M | 1.01M | 1.01M | 2.95M | 1.09M | 1.91M | 3.14M | 3.53M | 2.54M | 2.69M | 2.10M | 2.13M | 1.72M | 1.53M | 1.62M | 2.26M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| EBITDA | -139.03M | -104.20M | -66.08M | -45.64M | -49.67M | -72.60M | -104.02M | -124.44M | -125.53M | -116.53M | -77.68M | -54.41M | -38.84M | 4.67M | -33.07M | -44.96M | -19.07M | -18.16M | -16.50M | -11.82M | -10.21M | -12.81M | -22.30M | -14.13M | -9.96M | -6.95M | -7.31M | -11.30M | -11.10M | -8.70M | -8.50M | -4.10M | -5.90M | -3.80M | -1.40M | -1.30M | -1.80M | -1.40M |
| EBITDA Ratio | -2,019.96% | -4,321.89% | -1,452.55% | -514.92% | -1,628.10% | -6.66% | -753.60% | -2,008.62% | -2,388.18% | -3,385.86% | -1,909.44% | -508.72% | -453.12% | -7.08% | -219.49% | -240.92% | -416.70% | -453.96% | -566.77% | -178.53% | -225.49% | -200.04% | -720.66% | -995.26% | -713.91% | 1,677.27% | -150.00% | -1,118.18% | -367.50% | -94.29% | -107.78% | -74.24% | -46.08% | -20.18% | -25.64% | -56.52% | -104.55% | -1,900.00% |
| Operating Income | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M | -129.54M | -122.43M | -81.44M | -58.08M | -43.40M | -6.46M | -36.85M | -48.76M | -22.85M | -22.37M | -18.87M | -13.58M | -11.73M | -14.43M | -24.56M | -15.44M | -11.94M | -7.90M | -7.70M | -11.80M | -11.80M | -9.50M | -9.40M | -4.70M | -4.40M | -1.90M | -1.60M | -2.00M | -1.60M | -1.90M |
| Operating Income Ratio | -2,245.27% | -4,889.01% | -1,531.78% | -854.06% | -1,540.19% | -1,640.13% | -953.68% | -1,958.68% | -2,363.89% | -3,414.11% | -1,981.08% | -518.45% | -468.42% | -13.79% | -242.75% | -653.96% | -447.88% | -453.60% | -610.85% | -198.03% | -253.28% | -215.25% | -734.07% | -2,023.17% | -805.14% | -359.09% | -641.67% | -1,072.73% | -295.00% | -135.71% | -104.44% | -71.21% | -43.14% | -17.43% | -20.51% | -43.48% | -72.73% | -1,900.00% |
| Total Other Income/Expenses | 13.11M | 2.91M | 505.00K | 2.41M | 4.15M | 4.49M | 4.21M | 4.39M | 2.34M | 4.35M | -108.00K | -1.05M | -1.35M | 3.92M | -4.20M | 1.26M | -6.25M | 2.11M | 768.45K | 378.60K | 239.80K | 602.70K | 1.81M | -6.53M | 635.20K | 49.60K | -5.50M | 1.00M | 3.60M | -2.10M | 1.20M | 800.00K | 3.00M | 3.30M | 1.00M | 800.00K | 1.30M | 100.00K |
| Income Before Tax | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -37.05M | -62.26M | -21.76M | -20.25M | -18.10M | -13.20M | -11.49M | -13.83M | -22.75M | -21.98M | -11.31M | -7.90M | -13.20M | -10.80M | -8.20M | -11.60M | -8.20M | -3.90M | -3.50M | -1.10M | -900.00K | -1.20M | -700.00K | -1.80M |
| Income Before Tax Ratio | -2,054.76% | -4,765.59% | -1,520.92% | -821.61% | -1,423.96% | -1,593.09% | -920.61% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -244.10% | -835.04% | -426.40% | -410.74% | -585.96% | -192.51% | -248.10% | -206.26% | -680.03% | -2,879.32% | -762.33% | -359.09% | -1,100.00% | -981.82% | -205.00% | -165.71% | -91.11% | -59.09% | -34.31% | -10.09% | -11.54% | -26.09% | -31.82% | -1,800.00% |
| Income Tax Expense | 0.00 | 10.46M | -227.00K | -1.17M | -506.00K | -765.00K | -24.28M | -8.77M | -2.34M | -4.35M | -819.00K | -530.00K | -446.00K | -5.31M | -529.00K | 27.00M | -120.00K | 120.00K | -1.54M | -757.20K | 695.70K | -1.21M | -3.62M | 13.07M | -1.27M | 87.70M | 10.90M | -2.00M | -7.10M | 4.20M | -2.80M | -1.90M | -1.90M | -1.70M | -1.20M | -1.60M | -1.70M | -300.00K |
| Net Income | -141.43M | -122.78M | -70.51M | -59.78M | -50.37M | -151.18M | -93.03M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -36.53M | -47.50M | -21.64M | -20.37M | -18.10M | -13.20M | -12.67M | -13.83M | -22.75M | -21.98M | -11.31M | -51.80M | -13.10M | -10.80M | -8.30M | -11.60M | -7.80M | -3.60M | -3.40M | -1.00M | -1.10M | -1.20M | -800.00K | -1.70M |
| Net Income Ratio | -2,054.76% | -5,209.29% | -1,516.04% | -805.88% | -1,409.80% | -1,585.07% | -730.06% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -240.61% | -637.12% | -424.05% | -413.17% | -585.96% | -192.51% | -273.47% | -206.26% | -680.03% | -2,879.32% | -762.33% | -2,354.55% | -1,091.67% | -981.82% | -207.50% | -165.71% | -86.67% | -54.55% | -33.33% | -9.17% | -14.10% | -26.09% | -36.36% | -1,700.00% |
| EPS | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| EPS Diluted | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| Weighted Avg Shares Out | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
| Weighted Avg Shares Out (Dil) | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET....
Celldex: Long List Of Failures, High Valuation, But Good Data Recently
Celldex has failed too many times to inspire confidence. The company's current valuation is also quite high.
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Conference today at 9:20 am ET. A webcast of the presentation will be...
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phase...
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild.
Source: https://incomestatements.info
Category: Stock Reports